AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03340766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Up to 2 cycles of blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion.
Study NCT03340766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: One cycle of pembrolizumab is a 200 mg IV injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.
Study NCT00877500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care
Study NCT00877500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Given IV
Study NCT03772119 — intervention group
Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical resection of hemivertebra
Study NCT03558867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin + Healthy diet
Description: Metformin (1500 mg/d, Extended Release) + Healthy, low fat diet
Study NCT03558867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin + Personalized diet
Description: Metformin (1500 mg/d, Extended Release) + Algorithm-based personalized diet
Study NCT06021717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine-Morphine
Description: PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
Study NCT06021717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: PCA morphine (Pfizer Inc., US) 1 mg ml-1
Study NCT01962493 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sodium bicarbonate/ Sodium Fluoride
Description: Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic
Study NCT01962493 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride
Description: Toothpaste containing sodium fluoride as cosmetic
Study NCT01962493 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chlorhexidine digluconate
Description: Mouthwash containing chlorhexidine digluconate
Study NCT04428502 — intervention group
Intervention type: DRUG
Intervention: Enbrel
Description: As provided in real world practice
Study NCT04416828 — intervention group
Intervention type: DEVICE
Intervention: Portable wireless ultrasonography devices
Description: Patients with suspected ganglion cyst of the wrist or hand receive portable wireless ultrasound imaging
Study NCT04416828 — intervention group
Intervention type: DEVICE
Intervention: Cart-based ultrasonography device
Description: Patients with suspected ganglion cyst of the wrist or hand receive conventional cart-based ultrasound imaging
Study NCT01602198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exelon [rivastigmine] transdermal patch
Description: Exelon patch 1/day for six months
Study NCT01602198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal patch
Description: Placebo transdermal patch 1/day for 6 months
Study NCT03208257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Esmolol hydrochloride infusion
Study NCT02803645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study NCT04500691 — intervention group
Intervention type: OTHER
Intervention: pain intensity reporting
Description: pain intensity reporting
Study NCT01677403 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tobramycin
Description: Nebulised 80mg twice daily
Study NCT01677403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Nebulised 5mls 0.9% Saline twice daily
Study NCT02657356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study NCT02657356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl capsules
Study NCT03768882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: 1000 mg of paracetamol (parol 10mg/ml Mefar, Turkey) intravenous (IV) was given 102 patients
Study NCT03768882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: Second group: dexketoprofen 50 MG (Arveles ampoule -İE Ulagay -Menarini,Turkey) intravenous (IV) was given 98 patients
Study NCT02902380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine group
Description: dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
Study NCT02902380 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: 0.9% saline infusion
Study NCT00628745 — intervention group
Intervention type: OTHER
Intervention: None. Observational Study.
Study NCT03470909 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Skin-Sparing Mastectomy (SSM)
Description: For patients undergoing SSM, 10 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented.
Study NCT03470909 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nipple-Sparing Mastectomy (NSM)
Description: For patients undergoing NSM, 14 points of interest in radial localization have been selected for investigation of the presence of residual breast tissue, i.e. comparing to SSM, 4 additional biopsies will be taken behind the peripheral part of the areola.~The points are located under the remaining skin envelope and will be investigated by performing small biopsies with a cervical biopsy forceps.~Additionally, the distance between the surface of the specimen and the glandular tissue will be explored at five points at the base of the removed breast.~These histological sections will be radially oriented.
Study NCT04403373 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist control
Description: waitlist control
Study NCT04403373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking exercise
Description: walking exercise
Study NCT04403373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity walking exercise
Description: walking exercise
Study NCT00970931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone plus amiloride
Description: Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
Study NCT00970931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral placebo once a day, for 18 months
Study NCT01538589 — intervention group
Intervention type: DRUG
Intervention: insulin aspart
Description: Prescribed by the physicians as a result of normal clinical practice
Study NCT03124173 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training session
Description: The subjects will be trained to realize several versions of a learning task of conditional visuo-motor associations.
Study NCT03124173 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: First fMRI session
Description: In this session (involving a condition specific to man and a condition that we are certain to obtain in the monkey), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and three Manual responses (3 MRI-compatible mouse buttons).
Study NCT03124173 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Second fMRI session
Description: In this session (involving a condition specific to man and a condition that we are almost certain to obtain in monkeys), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and Three orofacial responses (3 movements of the mouth).
Study NCT03124173 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Third session of fMRI
Description: In this session (involving a human-specific condition and a condition we hope to achieve in the monkey), subjects will have to learn by trial-error in successive trials, conditional associations between three abstract stimuli and three verbal or Vocals.
Study NCT02588352 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salt tablet
Description: Subjects will be given salt tablets and instructed to take 4 grams of sale three times a day (total of 12 grams of salt/day) for one week
Study NCT04188496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Test group
Description: The interventional group received the same conventional Chest physiotherapy Techniques for 30 minutes followed by 10 minutes rest. The patients then received additional 15 minutes protocol of thoracic joint mobilization
Study NCT04188496 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: received conventional Chest physiotherapy Techniques for 30 minutes (including deep breathing, diaphragmatic breathing exercises, Self-stretching exercises for accessory respiratory muscles, Respiratory Resistance training by incentive spirometer) followed by 10 min rest.
Study NCT01731860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Additional PET Scan
Description: Additional PET Scan with no additional radiopharmaceutical administration.
Study NCT00294320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldara (Imiquimod)
Description: 250mg of Imiquimod cream for application once daily 3 times per week.
Study NCT00294320 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle cream
Description: 250mg vehicle cream for application once daily 3 times per week.
Study NCT02387788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778
Description: Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
Study NCT03667170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN035
Description: subcutaneous injection
Study NCT04254263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pyrotinib
Description: pyrotinib 400 mg, orally once daily for one year
Study NCT04783792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic acid / phytochemical supplement
Description: Ascorbic acid / phytochemical supplement
Study NCT04783792 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: Ascorbic acid
Study NCT03648086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intestinal microbiota transplantation
Description: Participants in Exprerimental group take 6 times IMT with 2-week intervals
Study NCT04171986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mecapegfilgrastim
Description: Mecapegfilgrastim; 6 mg, d7, q3w, total 2 cycles.
Study NCT04034199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab is a human monoclonal antibody against receptor activator of nuclear factor kappa-B ligand (RANKL) and its use is associated with a reduced risk of vertebral, non-vertebral and hip fracture in post-menopausal women. RANKL plays a crucial role in the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). Its production is increased by GC, resulting in stimulated osteoprotegerin ligand production and increased bone resorption. Recent randomized controlled trial from Saag et al have shown that denosumab is more efficacious than risedronate in the improvement of BMD in GIOP patients. Denosumab has been confirmed efficacious in GIOP patients but its efficacy in high-risk osteopenia patients are not well studied. It is given subcutaneously at 60mg every 6 months.
Study NCT04034199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic acid belongs to bisphosphonates and is licensed for the treatment of GIOP and 2 RCTs found zoledronic acid has superior efficacy in improvement in BMD at lumbar spine or femoral neck at 12 months when compared to risedronate. It is given intravenously every year at a dosage of 5mg.
Study NCT04048720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention
Description: The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will be offered eight group FNI sessions.
Study NCT00183469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.
Study NCT00183469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lamotrigine
Description: If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.
Study NCT00183469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Divalproex (DIV) ER
Description: If the participant is naive to DIV and if LAM was initiated before the start of treatment with DIV, DIV can be started at any point of time in the study provided the participant has been on LAM for at least 2 weeks. DIV will be started at 500 mg and titrated by increments of 500 mg every 3 to 4 days until a therapeutic blood level is attained up to 2500 mg.
Study NCT00183469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.
Study NCT00507182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluorescence Spectroscopy
Description: 1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
Study NCT00529568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
Study NCT00529568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: double-blind matched placebo control daily oral administration
Study NCT02444182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: A half of the participants will be randomly allocated to the probiotics group. They will receive a probiotics lozenge twice a day for 4 weeks. Pre and Post intervention clinical exam will be conducted
Study NCT02444182 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A half of the participants will be randomly allocated to the placebo group. Lozenges with no probiotics will be given twice daily for 4 weeks. Pre and Post intervention clinical exam will be conducted
Study NCT01462474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.
Study NCT01462474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/m2, D1, D22, and D43(q3w)
Study NCT01462474 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation（IMRT）
Description: IMRT (Intensity-Modulated Radiation Therapy). Radiation is delivered to GTV at 70 Gy in 32-33 fractions, CTV1 at 60 Gy in 32-33 fractions and CTV2 at 54 Gy in 32-33 fractions
Study NCT00566631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
Study NCT03605771 — intervention group
Intervention type: OTHER
Intervention: Daily Clinical Practice
Description: The assignment of a patient to a specific therapeutic strategy will not be decided in advance by the study protocol, but will be determined by the usual clinical practice of medicine, and the decision to prescribe a specific treatment will be clearly dissociated from the decision to include a patient in the study. No intervention will be applied to patients, either diagnostic or follow-up, other than the usual clinical practice.
Study NCT00766506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fentanyl IONSYS
Description: Participants will receive 40 mcg of fentanyl dose up to a maximum of 240mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
Study NCT00766506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Morphine IV PCA
Description: Morphine sulphate solution will be administered intravenously (IV) by a patient-controlled analgesia (PCA) pump using set bolus doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
Study NCT02073188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iBGStar
Study NCT02073188 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Glucometer
Study NCT01431235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy for treating ADHD symptoms
Description: 5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker
Study NCT00821041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 6 weeks of relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training
Study NCT00479401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexol Extended Release
Study NCT00479401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexol Immediate Release
Study NCT00479401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02359734 — intervention group
Intervention type: OTHER
Intervention: Smart pump safety Intervention bundle for improving IV medication administration process with smart pump
Description: Smart pump safety intervention bundle includes three components--1) eliminating unauthorized medications; implement standardized discontinuation policy of medications, implement standardized keep vein open rates and keep vein open rate order sets, and implement standardized verbal order practice. 2) Implement standardized intravenous(IV) labeling and IV tubing labels. 3) Implement standardized drug library lists and drug library use policies
Study NCT01011907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
Study NCT01011907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
Study NCT02023320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose of blueberry dry powder
Study NCT02023320 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dose of blueberry dry powder
Study NCT00611741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide, Na supplements
Description: furosemide 20 mg, Na supplements 8g in divided doses/day for 5 days
Study NCT01771419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Loop-tip wire (Cook Medical) for the cannulation of the CBD
Study NCT01771419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cannulotome CT-25mm Cook Medical
Study NCT05966870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unsweetened flavored sparkling water
Description: Unsweetened sparkling waters are carbonated water with flavoring, completely unsweetened, which are commercially available in soda-like flavors like cola
Study NCT01683552 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aprepitant
Description: 125 mg on day 1; 80 mg on day 3; 80 mg on day 5